Thermo Fisher Scientific Aktie News

The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown dividends at 19.1% annually over five years, with many trading at significant discounts. Recent changes include six new additions, with expected long-term CAGRs near 20% based on dividend yield the...

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific announces R&D partnership with AstraZeneca BioVentureHub.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2025 before the market opens on Wednesday, October 22, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as fut...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.5 billion aggregate principal amount (the “Offering”) of the following notes: $500 million aggregate principal amount of its 4.200% senior notes due 2031 (the “2031 notes”) at the issue price of 99.874% of their principal amount; $750 million aggregat...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is sponsoring Lab of the Future Europe this week in Amsterdam, The Netherlands, and will demonstrate how the company's Thermo Fisher™ Connect Platform can integrate and future-proof laboratories. From Digital Ambition to Automated Intelligence In pharma and life sciences, digital transformation is no...

TORONTO--(BUSINESS WIRE)--BenchSci today announced a strategic partnership with Thermo Fisher Scientific Inc. to create AI-powered tools to accelerate R&D productivity.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea, has selected Thermo Fisher to provide advanced bioreactors and consumables for its newest facility. Dr. Park specializes in Adeno-associated virus-based (AAV-b...

Thermo Fisher is well positioned as a mission-critical partner in life sciences, with a recurring revenue base and strong end-to-end solutions. The company's strategic acquisitions and leadership in bioprocessing, cell and gene therapy as well as multi-omics reinforce its competitive moat and growth potential. Thermo Fisher's unmatched global distribution drives cross-selling, allowing customer...